These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 19347989)

  • 1. Plasma fractionation, a useful means to improve national transfusion system and blood safety: Iran experience.
    Cheraghali AM; Abolghasemi H
    Haemophilia; 2009 Mar; 15(2):487-93. PubMed ID: 19347989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economical impact of plasma fractionation project in Iran on affordability of plasma-derived medicines.
    Cheraghali AM; Aboofazeli R
    Transfus Med; 2009 Dec; 19(6):363-8. PubMed ID: 19778319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of blood transfusion system of iran: 2002-2011.
    Cheraghali A
    Iran J Public Health; 2012; 41(8):89-93. PubMed ID: 23113231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Availability of blood components and plasma derived medicines in Iran.
    Cheraghali AM
    Transfus Apher Sci; 2007 Aug; 37(1):3-7. PubMed ID: 17707696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A successful experience of the Iranian blood transfusion organization in improving accessibility and affordability of plasma derived medicine.
    Chegini A; Torab SA; Pourfatollah AA
    Transfus Apher Sci; 2017 Feb; 56(1):12-16. PubMed ID: 28214180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Four decades of National Blood Service in Iran: outreach, prospect and challenges.
    Pourfathollah AA; Hosseini Divkolaye NS; Seighali F
    Transfus Med; 2015 Jun; 25(3):138-43. PubMed ID: 26040645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Viral safety of recovered plasma for contract fractionation; an Iranian experience, 2006-2015.
    Amini-Kafiabad S; Pourfatollah AA
    Transfus Med; 2022 Feb; 32(1):64-70. PubMed ID: 34820928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of Iran national plasma contract fractionation program.
    Cheraghali AM
    Daru; 2012 Oct; 20(1):63. PubMed ID: 23351278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and Trends of Transfusion-Transmissible Viral Infections among Blood Donors in South of Iran: An Eleven-Year Retrospective Study.
    Farshadpour F; Taherkhani R; Tajbakhsh S; Gholizadeh Tangestani M; Hajiani G; Sharifi N; Taherkhani S; Nejadbolkheyr A
    PLoS One; 2016; 11(6):e0157615. PubMed ID: 27309959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The dynamics of contract plasma fractionation.
    Farrugia A; Scaramuccia D
    Biologicals; 2017 Mar; 46():159-167. PubMed ID: 28236560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of repeated blood donations on the iron status of Iranian blood donors attending the Iranian blood transfusion organization.
    Djalali M; Neyestani TR; Bateni J; Siassi F
    Int J Vitam Nutr Res; 2006 May; 76(3):132-7. PubMed ID: 17048192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Availability, safety and quality of blood for transfusion in the Americas.
    Cruz JR; Pérez-Rosales MD
    World Hosp Health Serv; 2005; 41(1):25, 27-31. PubMed ID: 15881823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of HIV-1 in blood donations following implementation of a structured blood safety policy in South Africa.
    Heyns Adu P; Benjamin RJ; Swanevelder JP; Laycock ME; Pappalardo BL; Crookes RL; Wright DJ; Busch MP
    JAMA; 2006 Feb; 295(5):519-26. PubMed ID: 16449617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Source Plasma Donation: The Experience of the Iranian Blood Transfusion Organization.
    Mohammadi S; Aghabozorg F; Balagholi S; Ferdowsi S; Sharifi S; Eshghi P
    Int J Hematol Oncol Stem Cell Res; 2022 Jul; 16(3):151-156. PubMed ID: 36694705
    [No Abstract]   [Full Text] [Related]  

  • 15. Seroprevalence of human immunodeficiency virus, hepatitis B and C viruses and syphilis infections among blood donors at the Muhimbili National Hospital in Dar es Salaam, Tanzania.
    Matee MI; Magesa PM; Lyamuya EF
    BMC Public Health; 2006 Jan; 6():21. PubMed ID: 16445860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in prevalence of hepatitis B virus infection among Iranian blood donors, 1998-2007.
    Kafi-abad SA; Rezvan H; Abolghasemi H
    Transfus Med; 2009 Aug; 19(4):189-94. PubMed ID: 19708860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The revision of the European blood directives: A major challenge for transfusion medicine.
    Folléa G; Aranko K;
    Transfus Clin Biol; 2015 Aug; 22(3):141-7. PubMed ID: 26056039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the prevalence of major transfusion-transmitted infections among Iranian blood donors using confidential unit exclusion in an Iranian population: Transfusion-transmitted infections among Iranian blood donors.
    Omidkhoda A; Gharehbaghian A; Jamali M; Ahmadbeigi N; Hashemi SM; Rahimi A; Soleimani M
    Hepat Mon; 2011 Jan; 11(1):11-3. PubMed ID: 22087109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of national blood safety profile: effect of contract fractionation of plasma in resource limited countries, the Moroccan experience.
    Boulahdid S; Benahadi A; Adouani B; Laouina A; Mehdaoui FE; Mokhtari A; Soulaymani A; Hajjout K; Alami R
    Haemophilia; 2014 Sep; 20(5):e359-62. PubMed ID: 25039933
    [No Abstract]   [Full Text] [Related]  

  • 20. Prevalence and trends of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus among blood donors in Iran, 2004 through 2007.
    Kafi-abad SA; Rezvan H; Abolghasemi H; Talebian A
    Transfusion; 2009 Oct; 49(10):2214-20. PubMed ID: 19527477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.